leadf
logo-loader
viewOrthocell Ltd

Orthocell receives nearly A$2.4 million in R&D tax incentive refund from Australian Government

The funds will be invested into the Striate+ partnering program, progression of CelGro® nerve repair regulatory approvals, and to advance the development and commercialisation of Ortho-ATI®.

Orthocell Ltd - Orthocell Ltd receives nearly A$2.4 million in R&D tax incentive refund from Australian government
The company has registered Striate+ as the new global brand for the CelGro dental bone and tissue regeneration product

Orthocell Ltd (ASX:OCC) has received a research and development (R&D) tax incentive refund of A$2,394,397 for the financial year 2019/2020 from the Australian Government. 

The funds will be invested into the Striate+ partnering program, progression of CelGro® nerve repair regulatory approvals and to advance the development and commercialisation of Ortho-ATI®. 

Further strengthens capital position

Orthocell managing director Paul Anderson said: “Following the recent US approval of Striate+, the receipt of the R&D tax incentive refund further strengthens our capital position and enables us to progress the Striate+ partnering program, CelGro® nerve repair regulatory approvals and development and commercialisation of Ortho-ATI®, delivering significant shareholder value.”

The R&D tax incentive is a government program to support Australian companies to undertake R&D activities in Australia, under which eligible companies can receive cash rebates of up to 43.5% of eligible expenditure on R&D activities.

Striate+ gets US FDA approval

Last week, the company received US Food and Drug Administration’s (FDA) 510(k) clearance to market and supply its CelGro collagen medical device for dental bone and tissue regeneration procedures in the US.

The company has registered Striate+ as the new global brand for the CelGro dental bone and tissue regeneration product.

With the US, EU and Australian market approval achieved and key opinion leaders (KOLs) actively engaging with the program, Orthocell is well-positioned to secure a distribution partner and establish Striate+ as the best-in-class dental resorbable collagen membrane.

The global peripheral nerve repair market is estimated to be worth more than US$7.5 billion per annum, with around 3 million procedures that could use the nerve repair product each year.

Quick facts: Orthocell Ltd

Price: 0.54 AUD

ASX:OCC
Market: ASX
Market Cap: $101.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell Ltd secures new US divisional patent for CelGro®

Orthocell Ltd's (ASX:OCC) Paul Anderson talks Proactive's Andrew Scott through a new US divisional patent they've secured for CelGro® that covers the method of manufacture of collagen medical devices and as an aid in the surgical repair of soft tissue injuries. Orthocell has already been granted...

1 week, 1 day ago

2 min read